Introduction {#Sec1}
============

The causes of encephalitis are numerous, and most patients undergo extensive testing to identify infectious etiologies. However, other etiologies need to be considered. In the late 1960s, an association between limbic encephalitis and malignancy was made, and, since then, a number of antineuronal antibodies, such as the intracellular anti-Hu and anti-Ma, have been discovered and found to be associated with a specific array of cancers, as well as neuropsychiatric symptoms \[[@CR1], [@CR2]\]. More recently, antibodies to neuronal extracellular membrane antigens have been recognized. One of these is the NR1 subunit of the *N*-methyl-D-aspartate receptor (NMDAR), which was first identified in 2007. Unlike its classic paraneoplastic counterparts, patients with this antibody may or may not have an associated neoplasm, and often respond to immunotherapy and tumor removal, if present \[[@CR2]\].

The California Encephalitis Project (CEP) was initiated in 1998 to identify the etiologic agents and define the clinical and epidemiologic characteristics associated with encephalitis. Over 3,000 cases have been referred to the CEP, and many have been characterized into clinical profiles \[[@CR3]\]. In 2007, the CEP was notified that one referred patient was diagnosed with an ovarian teratoma associated with NMDAR antibodies. This case, in combination with previous experience with cases of a similar phenotype and unclear etiology, as well as the increasing recognition of anti-NMDAR encephalitis worldwide, led us to a collaborative work with the University of Pennsylvania focused on the identification of similar cases within the context of CEP referrals \[[@CR2], [@CR4]--[@CR7]\]. The purpose herein is to describe patients within the CEP that tested positive for the NMDAR antibody and compare them with patients that had a confirmed viral etiology, so that infectious disease physicians can more readily identify those affected with this new, potentially treatable, immune-mediated disorder.

Methods {#Sec2}
=======

Patient selection/enrollment {#Sec3}
----------------------------

Specimens are referred to the CEP by their treating physicians for diagnostic testing. Patients are required to be immunocompetent, at least 6 months of age, and must meet the CEP case definition of encephalitis, by which patients must be hospitalized with encephalopathy with at least one of the following: fever, seizure, focal neurologic findings, cerebrospinal fluid (CSF) pleocytosis, or electroencephalographic or neuroimaging findings consistent with encephalitis. A standardized case history form is submitted by the referring physician with patient information on exposures, travel, laboratory findings, and clinical and demographic characteristics. This study was approved by an ethical standards committee, and subjects signed a consent form prior to NMDAR antibody testing.

CEP core testing {#Sec4}
----------------

CSF, respiratory specimens, and acute- and convalescent-phase serum specimens are submitted and tested for 16 potential infectious agents of encephalitis, including herpesviruses, enteroviruses, arboviruses, respiratory viruses, and *Mycoplasma pneumoniae* \[[@CR3]\].

Once the CEP became aware of the occurrence of anti-NMDAR+ encephalitis, collaboration with the University of Pennsylvania was established to facilitate the recognition and testing of anti-NMDAR+ cases within the CEP, as follows: retrospective testing of patients who had idiopathic encephalitis, along with dyskinesias or movement disorders; and prospective referral of cases based on similar syndromic features. Testing for NMDAR antibodies was performed as previously described \[[@CR6]\]. Samples from a limited number of patients with confirmed viral etiologies including enteroviral (EV), rabies, and herpes simplex-1 (HSV-1), varicella zoster virus, and rabies were selected and tested for NMDAR antibodies.

Data analysis {#Sec5}
-------------

Demographic, clinical, and laboratory data from anti-NMDAR+ patients were compared with data from encephalitis patients with confirmed EV and HSV-1, since these are the most commonly identified viral etiologies within the CEP. Rabies virus cases were also included for comparison because this diagnosis was strongly suspected by referring physicians in several cases that were ultimately found to be NMDAR antibody positive. Categorical data were analyzed using the Chi-square test, and continuous data were subjected to the Kruskal-Wallis test. Statistical significance was defined as *P* \< 0.05.

Results {#Sec6}
=======

Characteristics of anti-NMDAR+ cases {#Sec7}
------------------------------------

Of the 20 cases tested, ten anti-NMDAR+ cases were identified; two patients were identified by retrospective testing and eight cases were identified prospectively. All ten patients were negative for viral studies, but four had a positive serum *Mycoplasma* IgM. The demographic, clinical, laboratory, and imaging findings of the ten cases are summarized in Table [1](#Tab1){ref-type="table"}, while the frequencies are found in Table [2](#Tab2){ref-type="table"}. The median age was 18.5 years (range 11--31 years), and none were of Caucasian descent, while there was a predilection for Asians/Pacific Islanders (50%). Although 60% of patients presented with apparently benign symptoms, all had returned with more severe symptomatology within days. Nearly all patients demonstrated personality changes, and the majority (70%) displayed extreme irritability. Psychiatric symptoms were common and manifested earlier in the course of the illness, often at presentation. Psychotic symptoms were noted in 68% of subjects, with all of these patients experiencing hallucinations, particularly of the auditory nature. Other schizophrenia-like symptoms, including flat affect and disorganized thinking, were reported in three patients. Two subjects presented with seizures, and an additional 60% developed seizures after hospitalization, often of the tonic-clonic type, but sometimes in combination with focal episodes. Mental status changes were nearly universal, and care in the intensive care unit (ICU) was required; patients had a median Glasgow Coma Scale (GCS) score of 8. Table 1Listing of California Encephalitis Project (CEP) patients with *N*-methyl-D-aspartate receptor (NMDAR)-positive encephalitisAgeRace/ethnicityReason for initial presentationNeurologic abnormalitiesAutonomic instabilityAggression/irritabilityHallucinationsPersonality changeSeizuresLowest GCSNeoplasmLumbar puncture (LP) resultsMRIEEGGenderCSF WBCCSF proteinCSF glucose11Pacific IslanderLeft facial twitching with choreoathetoid movement of the arm and leg, headacheChoreoathetoid movements, ataxia, cranial nerve abn., tongue thrusting, facial twitching, aphasiaTachycardiaNYYY8Y, ovarian teratoma6^b^Abnormal; focal cerebritis of right, posterior frontal lobeRight hemisphere slowing; no epileptiform activityF235511AsianMental status changes, psychosis, mouth twitching and muscular spasticityAtaxia, mouth twitching, aphasiaTachycardia, hypertension, hyperthermiaYYes, auditory and visualYN14N16^b^NormalDiffuse slowing, no epileptiform activityM23Unk11AsianHeadaches, fever, psychosisAtaxiaNYY, olfactoryYY15N26 (94%L)NormalDiffuse slowing; no epileptiform activity(?)M296612Pacific IslanderMental status changesChoreoathetoid movementsTachycardia, hypertension, hyperthermiaYNUnkY8N170 (92%L, 2%M)Abnormal; dural and meningeal enhancementDiffuse slowing; some left frontal spikesF676618BlackBehavioral problemsAtaxia, cranial nerve abnormalities, aphasiaBlood pressure labilityYYYY4N100 (94%L, 6%M)NormalUnkF2207219White-HispanicInvoluntary rightarm and shoulder movementsChoreoathetoid movements, left facial droopYNNYN15N3 (89%L, 10%M, 1%P)Abnormal; basal ganglia hyperintensity, bilaterallyPolymorphic bilateral frontopolar and frontal slowingF275819BlackHeadache, personality change, nonsensical speechOrofacial dyskinesiasTachycardia, hypertension, hyperthermia, tachypnea, hypoventilationYY, auditoryYY3N18 (93%L, 4%M, 3%P)Abnormal; white matter demyelination (periventricular, thalamic,corpus callosum lesions)Diffuse slowing; no epileptiform activityM286222AsianPsychosisChoreoathetoid movements, orofacial dyskinesias, aphasiaTachycardia, hypertension, hyperthermia, tachypnea, hypoventilationYY, auditoryYY8N13 (84%L, 3%M, 11%P)NormalTemporal epileptiform activity with left\>rightM215727HispanicHeadaches, confusion, psychosisAtaxia, bruxisms, lingual dyskinesias, tongue biting, aphasiaTachycardia, hypertension, hyperthermia, hypoventilationNNYYUnkY, ovarian teratoma118 (85%L, 10%M, 5%P)NormalDiffuse slowing; no epileptiform activityF306331BlackHeadache, feverChoreoathetoid movements, ataxia, cranial nerve abn., with left eyedeviationTachycardia, hypertension, hyperthermia, tachypneaYUnk^a^YY3N34 (93%L, 7%M)NormalDiffuse slowing; no epileptiform activityF3358Y = yes; N = no; F = female; M = male; GCS = Glasgow Coma Scale; CSF = cerebrospinal fluid; WBC = white blood cell; abn. = abnormalities; MRI =magnetic resonance imaging; EEG = electroencephalogram; L = lymphocytes; M = monocytes; P = polymorphocytes^a^Severely altered, unable to report^b^Differential not done or unknownTable 2CEP NMDAR cases vs. confirmed viral casesNMDAR (*n* = 10)Confirmed HSV-1 cases (*n* = 52)Confirmed enterovirus cases (*n* = 85)Confirmed rabies cases (*n* = 6)DemographicsAge, median, years18.5 (range 11--31)46.0 (range 0--89)14.0 (range 0--75)38.5 (range 11--72)GenderMale4 (40%)26 (50%)52 (61%)6 (100%)Female6 (60%)26 (50%)33 (39%)0EthnicityWhite, Hispanic2 (20%)8 (15%)26 (31%)1 (17%)White, non-Hispanic027 (52%)30 (35%)1 (17%)Black3 (30%)2 (4%)7 (8%)0Asian/Pacific Islander5 (50%)3 (6%)10 (12%)2 (33%)Other/unknown012 (23%)11 (13%)2 (33%)Clinical findingsGeneral symptomsFever7 (70%)46 (88%)63 (74%)4 (67%)GI5 (50%)19 (36%)35 (41%)5 (83%)URI1 (10%)11 (21%)24 (28%)4 (67%)Rash03 (6%)15 (18%)0Intubation6 (60%)8 (15%)4 (5%)5 (83%)ICU admission8 (80%)30 (58%)28 (33%)4 (67%)Seizures8 (80%)30 (58%)24 (28%)2 (33%)Coma3 (30%)8 (15%)5 (6%)5 (83%)Died1 (10%)9 (17%)5 (6%)6 (100%)Neurologic symptomsAltered consciousness5 (50%)32 (62%)31 (36%)4 (67%)Ataxia6 (60%)7 (13%)23 (27%)0Focal neurologic signs6 (60%)17 (33%)24 (28%)2 (33%)Stiff neck3 (30%)16 (31%)27 (32%)0Cranial nerve abnormality3 (30%)03 (4%)0Psychiatric symptomsHallucinations6/9 (67%)8 (15%)9 (11%)1 (17%)Psychosis6/9 (67%)1 (2%)2 (2%)0Personality change10 (100%)15 (29%)7 (8%)2 (33%)Irritability7 (70%)11 (21%)29 (34%)1 (17%)Laboratory data^a^CSFWBC, median (range), per mm^3^22 (range 3--170)90 (range 0--110)55.5 (range 0--1,332)3.5 (range 0--10)Protein, mg/dL28.5 (range 21--220)65 (range 6--297)54 (range 16--881)35 (range 32--172)Glucose, mg/dL62 (range 55--72)68 (range 39--112)66 (range 27--159)65 (range 60--110)Neuroimaging abnormality^a^MRITemporal lobe036 (69%)4 (5%)0Hydrocephalus01 (2%)00White matter involvement1 (10%)4 (8%)4 (5%)0Cerebral edema01 (2%)00CTTemporal lobe014 (27%)00Hydrocephalus01 (2%)3 (4%)0White matter involvement01 (2%)2 (2%)0Cerebral edema0000EEGSlowing8 (80%)9 (17%)7 (8%)2 (33%)Epileptiform activity1 (10%)7 (13%)2 (2%)0PLEDs04 (8%)1 (1%)0CSF = cerebrospinal fluid; WBC = white blood cell; MRI =magnetic resonance imaging; CT = computed tomography; EEG =electroencephalogram; PLEDs = periodic lateralized epileptiform discharges; ICU = intensive care unitDenominators used in the calculations may vary, depending on the available data^a^Data are from initial neuroimaging studies or initial lumbar puncture

Choreoathetoid movements, ataxic gait, cranial nerve abnormalities, repetitive orofacial movements, and aphasia were each reported in around half of the patients. Subjects suffered from various combinations of neurologic findings, but 90% of patients experienced at least two or more abnormalities, while 60% demonstrated three or more abnormal neurologic findings. Sixty percent of those with orofacial dyskinesias had movements limited to the mouth alone, including lip smacking, tongue protrusion, and bruxism, each unassociated with a seizure focus on EEG when concurrent motor activity was present. None of the patients were believed to acquire these findings as a result of anti-psychotic medications, but, in one case, the medication did precede the development of symptoms. Choreoathetoid movements and dyskinesias were also highly variable from patient to patient, with no distinct pattern in terms of rate or rhythm (Table [1](#Tab1){ref-type="table"}). Dysautonomia was nearly ubiquitous in anti-NMDAR+ patients, observed in 89% of cases. Tachycardia and bradycardia, blood pressure lability, hyperthermia, hypoventilation, and/or apnea were each reported in most patients with autonomic instability. Many patients experienced three or more types of instability, making these symptoms prominent clinical manifestations (Table [1](#Tab1){ref-type="table"}).

Laboratory, EEG, and neuroimaging findings {#Sec8}
------------------------------------------

The majority of anti-NMDAR+ patients (89%) demonstrated a lymphocytic pleocytosis during the course of illness, with a median CSF white blood cell (WBC) count of 26/μl on presentation. The median CSF protein concentrations were elevated, but the CSF glucose was often within normal limits. EEG monitoring revealed diffuse slowing almost universally. Focal epileptic activity was uncommon (10%) and paroxysmal discharges were not observed (Table [1](#Tab1){ref-type="table"}).

Computed tomography (CT) rarely revealed abnormalities. While magnetic resonance imaging (MRI) was normal on admission in all patients, changes were demonstrated in 40% of subjects on follow-up studies. However, the findings on MRI, for both fluid-attenuated inversion recovery (FLAIR) and T2-weighted images, were not consistent from patient to patient. Periventricular white matter demyelination and other nonspecific findings were observed in one case, and temporal lobe abnormalities were notable in others. Nonspecific abnormalities, or, often, no abnormality at all, appeared to be the standard for these patients.

Comparison of anti-NMDAR encephalitis with viral encephalitis {#Sec9}
-------------------------------------------------------------

Samples from 16 cases with confirmed viral etiologies were all negative upon testing for anti-NMDAR antibodies. Comparison of anti-NMDAR+ patients to those with viral etiologies of encephalitis revealed significant differences (Table [2](#Tab2){ref-type="table"}). Viral cases were not disproportionately common among Asians or Pacific Islanders (*P* \< 0.05 for HSV-1, EV, and rabies-associated encephalitides). Psychosis was significantly less common in all viral groups with frequencies of 0 to 2% (*P* \< 0.0001), and the presence of hallucinations was also less likely (*P* \< 0.05 for all groups). Personality changes, though more frequent in HSV-1 and rabies virus patients, were seen significantly less often in encephalitic subjects with a viral etiology (*P* \< 0.0001 for all groups). Seizure activity was observed less often among virus-infected individuals, though not statistically less so among those with HSV-1 encephalitis (*P* \< 0.001 for EV and rabies cases).

Laboratory studies revealed that the CSF WBC median was higher in those with EV and HSV-1 (90 and 56 cells per μl, respectively) than in those with anti-NMDAR+ encephalitis (22 cells per μl). Rabies virus cases rarely demonstrated CSF pleocytosis, with a median count of 3.5 cells per μl (*P* \< 0.05). The median CSF protein concentrations were significantly higher in those with viral causes, with the exception of those with rabies (65 mg/dl in HSV-1 and 54 mg/dl in EV vs. 28 mg/dl in anti-NMDAR+ patients; *P* \< 0.05 for both), but the CSF glucose concentrations did not differ. Temporal lobe changes on neuroimaging were more common in patients with HSV-1 (27 and 69%, respectively; *P* \< 0.05).

Overall, viral causes, and especially EV encephalitis, appeared to cause fewer severe complications, including a lower rate of alteration in consciousness (36 vs. 50%), ICU admission (33 vs. 80%), and intubation (5 vs. 60%). Despite a good outcome for most patients with anti-NMDAR encephalitis, this is a severe disorder that may result in death. In the current study, 10% of anti-NMDAR+ patients died of this disorder, a number that is higher than those who died of EV (6%), although lower than the mortality associated with HSV-1 (19%) and rabies (100%).

Discussion {#Sec10}
==========

When patients present with clinical features of encephalitis, viral etiologies are among the primary considerations in establishing a diagnosis, with HSV-1 and EV being among the most common offending agents \[[@CR3], [@CR8], [@CR9]\]. Viral testing can be time consuming and, if it is unable to reveal the cause for the patient's condition, can leave clinicians confounded as to how to proceed with further testing or treatment. Autoimmune etiologies should be considered in the differential diagnosis, even at initial presentation.

Despite the small sample of anti-NMDAR+ patients, there are clinical features that appear to be common in patients with anti-NMDAR+ encephalitis, and which correlate with those reported in other case series describing similar encephalitic patients. While prodromal symptoms were not highly patterned in the patients in this study, others have noted a consistent 'flu-like' viral illness prior to or with initial presentation, though most patients herein did report fever and headache \[[@CR2], [@CR10]--[@CR18]\]. The progression of illness noted in this series did, however, resemble that described in other studies.

Anti-NMDAR+ encephalitic patients appear to develop a somewhat predictable course of illness, during which a number of symptoms are frequently observed. Psychiatric symptoms manifest early in the course of illness, and patients are likely to display schizophrenia-like behaviors, such as psychosis and hallucinations. This is consistent with the observation that NMDAR antagonists can cause healthy individuals to develop schizophrenia-like symptoms \[[@CR19]--[@CR21]\]. A newly published study also revealed that antibodies from patients with anti-NMDAR receptor encephalitis cause a dramatic decrease in the number of NMDAR postsynaptic clusters in neuronal cultures, suggesting a decrease in NMDAR function \[[@CR22]\]. Behavior and personality changes, sometimes with notable aggression, appear to be additionally remarkable in patients with this form of encephalitis \[[@CR2], [@CR10]--[@CR18], [@CR22]\]. Continued decompensation is the norm in these patients, with most requiring intensive care monitoring and possibly ventilatory support. Hypoventilation, in particular, has been described as a significant feature of this illness, affecting 66% of those in a 100-patient series \[[@CR22]\]. Other neurologic symptoms also develop in nearly every patient, including dystonias, orofacial movements, particularly oral dyskinesias, and choreoathetosis; none of these have epileptic origins. However, seizures themselves, often of a tonic-clonic nature, are common, with no correlative epileptiform discharges that permitted localization on EEG \[[@CR2], [@CR16]--[@CR18], [@CR22]\]. Mental status changes, though seen in some patients at presentation, consistently developed later in the course of illness, with many patients becoming non-responsive and non-verbal, and displaying low GCS scores. Autonomic instability is almost always observed.

Specific demographic characteristics were notable among our cases and, at times, possibly as a result of the small anti-NMDAR+ sample size, at odds with previous reports. There were a larger number of males in our series, which is likely a result of the selection process. However, it may also be that males have been less readily recognized with this diagnosis, as there have been inconsistent associations with concurrent neoplasms, making clinicians hesitant to attribute symptoms to this specific cause. It is not clear whether or not these individuals would ultimately be found to have tumors, or whether, as with other autoimmune encephalitides (e.g., that are associated with voltage-gated potassium channels), a substantial percentage of patients simply did not harbor neoplasms \[[@CR23], [@CR24]\]. This is often difficult to ascertain, as many paraneoplastic syndromes can precede the discovery of associated tumor by years \[[@CR2]\].

Patients were also more likely to be of Asian or Pacific Islander descent, a finding suggested by a recent publication from Japan \[[@CR15]\]. This was surprising, given that teratomas, which are the most common tumors associated with anti-NMDAR encephalitis, demonstrate no racial bias, though malignant ones are more common among Asians \[[@CR25]\].

In the present series, the median age was younger than that in prior studies, in which a higher percentage of patients with teratomas were identified \[[@CR2], [@CR7], [@CR10]--[@CR18], [@CR22]\]. Given the small number of subjects, it is difficult to ascertain whether the true median age for this entity is as low as 18.5 years, but it is notable that a number of subjects in the current series were children. Those as young as 5 years of age have been described elsewhere, and the median age appears to be distinctly younger than that seen among those with classic paraneoplastic syndromes \[[@CR2], [@CR14], [@CR16]\]. Only 20% of those examined herein had ovarian teratomas, and, interestingly, of those without tumors, 50% had positive *Mycoplasma* IgM serologies. As previously reported, the significance of an isolated positive *M. pneumoniae* serum IgM, especially without signs of *Mycoplasma* IgG change or polymerase chain reaction (PCR) positivity is unknown \[[@CR26]\]. On average, only about 10% of CEP patients have positive serology for *M. pneumoniae*, making this percentage higher than generally expected. This observation lends itself to the speculation that anti-NMDAR+ patients may develop encephalitis as a result of a post-infectious, antibody-mediated process such as that observed in Sydenham's chorea or other pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAs) in which antistreptococcal-antineuronal antibodies are thought to destroy healthy nervous system cells which serve as molecular mimics \[[@CR27]--[@CR29]\]. Because the association with *M. pneumoniae* is not fully understood, clinicians should be cautioned against accepting *M. pneumoniae* as the sole explanation for an encephalitic illness, especially if this diagnosis is based on a single IgM test.

The differentiation of anti-NMDAR+ associated encephalitis from encephalitis of viral origin on clinical grounds alone is difficult, although our study reveals that there may be some useful clues. HSV-1 patients will typically be older than anti-NMDAR+ patients, and are less likely to display severe psychiatric disturbances and schizophrenia-like symptoms. HSV-1 encephalitis patients are also not as likely to display combinations of movement disorders, such as choreoathetosis and orofacial dyskinesias, as those with anti-NMDAR encephalitis \[[@CR28], [@CR29]\]. Autonomic instability is not a predominant feature of HSV. Focal EEG abnormalities of the temporal lobe may also point to a viral etiology and, of course, a positive HSV PCR in the CSF is a defining feature of herpes simplex encephalitis \[[@CR3], [@CR9], [@CR30], [@CR31]\].

EV encephalitis, like HSV-1 encephalitis, is generally associated with a higher WBC count and protein concentration in the CSF when compared to patients with anti-NMDAR+ encephalitis. Neuroimaging is nonspecific in these patients, but symptomatology can play a substantial role in differentiating these two etiologies because psychiatric and focal neurologic findings will be much less likely. Patients with EV-associated encephalitis are less apt to decompensate and become non-responsive and unable to verbally communicate. Autonomic instability with subsequent ventilatory support plays a much more subtle role in EV-affected individuals and, as with HSV-1 encephalitis, EV can be detected in the CSF \[[@CR31], [@CR32]\].

Rabies virus cases pose a particular diagnostic challenge because behavioral symptoms can be as prominent as they are with anti-NMDAR encephalitis. Exposure history, along with diagnostic testing for rabies, is of great value. Typically, more than one diagnostic test will be required to diagnose rabies encephalitis in antemortem patients, while a brainstem biopsy alone is required in post-mortem individuals \[[@CR33]\].

The study results do merit a few additional considerations. Reports of cranial nerve abnormalities, ataxic gait, and aphasic findings, obtained from CEP questionnaires, can be subjective in their interpretation. For example, it may be that facial nerve dysfunction and ocular deviations were, in reality, of central origin, as oculogyric crises and facial dystonias have been reported to occur in anti-NMDAR+ patients \[[@CR16], [@CR22]\]. Yet, despite their variable interpretation, gait, facial, and verbal abnormalities, whether of central origin or not, are noted in many cases and can assist in suggesting a diagnosis. Furthermore, though many of our positive confirmed viral cases were not tested for the presence of NMDAR antibodies, samples from 16 patients within the CEP cohort with confirmed viral etiologies were negative for NMDAR antibodies, and based on previous work by Dalmau et al. \[[@CR22]\], the antibody is both highly sensitive and specific. It binds to a distinct region of the NMDAR. Although viral encephalitis, stroke, chronic epilepsy, and lupus have been associated with NMDAR antibodies, the region of the NR1 portion of the receptor to which the NMDAR antibodies bind appears to be uniquely associated with anti-NMDAR encephalitis, as opposed to other conditions.

The management of anti-NMDAR+ encephalitis can prove to be very effective and involves the identification and treatment of the tumor, along with immunotherapy. In a series of 100 cases, 91 were women, and 63% had a tumor, primarily an ovarian teratoma. Only 2 of the 9 men had a tumor (one teratoma of the testis and one small-cell lung cancer). Patients with prompt tumor removal and immunotherapy (e.g., steroids) had better outcomes and fewer neurological relapses than those whose tumor was not treated or who had no tumor. Nevertheless, patients of the latter groups also responded to immunotherapy. Overall, 75% recovered or had mild deficits, while 18% had severe deficits, with 7% dying as a result of the encephalitis \[[@CR22]\].

Larger studies are needed to estimate the true incidence of anti-NMDAR encephalitis among cases that, after extensive viral screenings, have previously been considered as 'idiopathic encephalitis,' 'encephalitis of unclear etiology,' or 'encephalitis lethargica.' Among these, our study shows that certain clinical profiles such as "encephalitis with dyskinesias or abnormal movements" are likely to be frequently related to anti-NMDAR encephalitis. Of the approximately 20 samples tested, ten (50%) were positive, suggesting that this syndrome is a relatively common cause of encephalitis and should be routinely considered in patients with characteristic clinical features. Moreover, although the set of symptoms associated with anti-NMDAR encephalitis is highly predictable and the frequency of dyskinesias very high \[[@CR34]\], our study likely underestimates the true incidence of this disorder by focusing on a profile based on 'dyskinesias or abnormal movements,' and excluding milder forms or 'formes frustes,' such as those associated with 'psychiatric symptoms and seizures' with minimal or absent abnormal movements \[[@CR35]\].

Anti-NMDAR+ encephalitis is a recognizable, diagnosable, and treatable illness. Patients, in general, will have good outcomes, particularly with aggressive and prompt therapy. Clinicians must be aware of this condition, especially when evaluating patients with encephalitis.
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